



Monitoring for Adverse Reactions to TB Medications

Melissa Davis, RN
January 22, 2025

Introduction to TB Nurse Case Management Online
Wednesdays, January 15 – February 5, 2025
Online from San Antonio, Texas

Melissa Davis, RN has the following disclosures to make:

- No conflict of interests
- No relevant financial relationships with any commercial companies pertaining to this educational activity





TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Monitoring for Adverse Reactions to TB Medications

Melissa Davis, RN

TB Program Manager,

Texas Department of State Health Services, Region 11

Special Thanks to Mathew Whitson, RN,
Communicable Disease Consultant, Region 8



Objectives

- Describe the monitoring process for adverse drug events associated with anti-TB drugs.
- Examine the difference between side effects and drug toxicities.
- List the most common adverse effects of TB therapy.

Preparing for medication administration



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Obtain patient information
 - Patient's weight
 - Patient's medications
 - Patient's past medical history
- Establish a rapport with the patient
 - Determine what barriers you may encounter
- Draw baseline labs
 - CBC, CMP (with creatinine level), Glucose, HIV test



Preparing for medication administration



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Provide education to the patient and additional family members as needed.
 - Treatment will be for months, not days.
 - Provide educational materials on medications and side effects.
 - What are the expectations of the patient? The nurse?
- Provide notification to the patient's physicians.
 - Critical if medications interact with each other.



Preparing for medication administration



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Medication classes that can decrease in efficacy
 - Beta blockers
 - Anticoagulants
 - Anti-depressants
 - Anti-diabetic drugs
 - Anti-anxiety agents
 - Anti-psychotics
 - ACE inhibitors
 - HMC CoA Inhibitors (statins)
 - Hormonal Contraceptives
 - Immunosuppressants
 - Opiates
- May need dosage adjustment.



Preparing for medication administration



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Perform baseline toxicity screening.
 - Are signs and symptoms of toxicity present before medications administered?
 - Are baseline labs normal?
 - Vision screening
 - Red/green color discrimination
 - Visual acuity
- Ensure that the medication orders are correct.





TEXAS
Health and Human Services

Texas Department of State
Health Services

Baseline: Prior to Starting Anti-TB meds

- Medical History
- MD/RN evaluation
- Chest X-ray
- Sputum Specimen
- HIV Testing
- Toxicity assessment
 - Vision screenings
- Weight
- Labs (CBC, CMP, etc.)

Texas Department of State Health Services Clinical Assessment for Tuberculosis Medication Toxicity										
NAME: _____		D.O.B.: ____/____/____		SS#: ____/____/____						
<small>Adverse Drug Reaction Assessment: Ask all the below questions to monitor for medication toxicity, noting that some symptoms may be more commonly associated with certain medications. Those with** are associated with second-line drugs; those with † are associated with Isoniazid/Rifapentine (3HP) but may also be present in other regimens. Document any [+], incl. potential pregnancy in women, in progress notes & notify physician. Results: [+]=Present; [-]=Denies; [NA]=Not Applicable</small>										
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Weight										
Temperature										
Blood Pressure										
Pulse										
Do you have any of the following symptoms now or since your last clinic appointment?										
Abdominal pain/diarrhea** †										
Abnormal behavior**										
Allergic reaction (specify)** †										
Bruises, red/purple spots on skin†										
Change in heart rate**										
Change in urine output										
Convulsions**										
Dark urine (coffee colored) or change in color†										
Ears ringing/fullness/hearing loss** - AK,CAP,KM, SM										
Eye pain/irritation (redness, excessive tears)										
Fever or chills†										
Flu-like symptoms†										
Headaches (chronic)										
Increased gas/stomach cramps**										
Jaundice (yellow skin/eyes)										
Joint pain/swelling (chronic) - PZA										
Light colored stools†										
Loss of appetite†										
Malaise/fatigue										
Memory Loss**										
Mood changes/depression**										
Musculoskeletal Pain†										
Nausea/vomiting†										
Numbness/tingling/pain, arms, legs†										
Nervousness/Giddiness/Restlessness										
Skin discoloration**										
Skin rashes/itching†										
Sleep problems**										
Sores on lips or inside mouth†										
Shortness of breath†										
Teeter/Fall to Left or Right when standing (eyes closed)										
Unusual bleeding (nose, gums, stool, urine, etc.) or easy bruising - RIF, RPT†										
Vertigo/dizziness/fainting†										
Visual problems/changes in vision*** - EMB, RBT										
Weakness, tiredness†										
Weave/Stagger when walking (normal gait)										
Use of over the counter drugs, ie. Tylenol products?										
Ask women about signs of pregnancy										
Drug Issued	Mfg/Lot#/Exp	Route/Frequency	Amount	Amount	Amount	Amount	Amount	Amount	Amount	Amount
Name/Title										
Interpreter										
Next Appt.										

Baseline: Prior to Starting Anti-TB meds



TEXAS
Health and Human Services

Texas Department of State Health Services

Texas Department of State Health Services Vision/Hearing Screening Form

NAME: _____ D.O.B.: ____/____/____ SS#: ____/____/____

Red/Green Color Discrimination:
The (X) mark indicates the plate cannot be read. Screen all 14 plates. Client must pass 10 of the first 11 plates for the test to be regarded as normal. Refer for evaluation if ≥ 7 plates are read as normal.
Results: [N] = Normal [A] = Abnormal

Ishihara Plate #	Normal Reading	Red/Green Deficiency	Date	Date	Date	Date	Date	Date	Date	Date	Date
1	12	12									
2	8	3									
3	5	2									
4	29	70									
5	74	21									
6	7	X									
7	45	X									
8	2	X									
9	X	2									
10	16	X									
11	Unreadable	X									

Ishihara Plate #	Normal Reading	Red/Green Deficiency	Prostan		Deutan		Date	Date	Date	Date	Date	Date
			Strong	Mild	Strong	Mild						
12	35	5	(3) 5	3	3 (5)							
13	96	6	(9) 6	9	9 (6)							
14	Can trace 2 lines	Purple (Red)	Purple (Red)	Red (Purple)	Red (Purple)							

Results
Initials: _____

Visual Acuity:
If initial screen was conducted with corrective lenses (glasses or contacts), follow-up screens must be done the same. A change of 1 or more lines from the initial screen in either one or both eyes must be reported to the physician immediately.
Results: [P] = Pass [F] = Fail [U] = Unscreenable Chart Used: [] Letter [] "E" [] Other, Specify: _____
Corrective Lenses: [] = Yes [] = No

Distance Acuity	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Right Eye	20/	20/	20/	20/	20/	20/	20/	20/	20/	20/
Left Eye	20/	20/	20/	20/	20/	20/	20/	20/	20/	20/
Both Eyes	20/	20/	20/	20/	20/	20/	20/	20/	20/	20/
Results										
Initials:										

Hearing Sweep Check:
When patient is taking amikacin, capreomycin, kanamycin, or streptomycin, for each of the four frequencies listed, record the lowest level in decibels (dB) at which the person responds. Record the findings for both the right and left ear. Refer to an appropriately licensed professional if any two of the four frequencies are recorded as greater than 25 dB in either ear or the same ear or if there is a change of decreased hearing level from baseline. Start with 40 dB, if heard decrease by 10 dB until no response is obtained or until 20 dB is reached. If 20 dB is heard, record as 20 dB. Once no response is obtained, increase the dB level by 5 until a response is obtained and recorded. If a response is not heard at 40 dB, record as 40+ dB.
Results: [P] = Pass [R] = Refer [O] = Observe Ear: [R] = Right [L] = Left

Frequency	Date		Date		Date		Date		Date		Date	
	R	L	R	L	R	L	R	L	R	L	R	L
500 Hz												
1000 Hz												
2000 Hz												
4000 Hz												
Results												
Initials:												

TB105- Clinical Assessment for TB Medication Toxicity - Revised 8/2017

*** From previous page: Changes in Vision may include blind spots in field of vision, blurred vision, changes in peripheral vision

Texas Department of State Health Services Tuberculosis Case and Suspect Management Plan

Patient's Name: _____ Initial Report Date & Source: _____

Nurse Case Manager: _____ Case Management Team: _____

Directions: Blank boxes indicate week(s) TB service is to be provided. Document date and initials of the provider in the appropriate box when the task is completed. Document comments in progress notes.

		Action Interval:	0	2	4	8	12	16	20	24	26
			Begin	Wks	Wks	Wks	Wks	Wks	Wks	Wks	Wks
		Date:									
Consents	General Consents, L-30, L-36, HIPAA, TB-209, interpreter form PRN; TB 409, TB 410, TB 411, etc.										
Responsibility	Assign nurse case manager; establish team; document in client's record										
Medical Evaluation	Obtain medical history; document on TB-202										
	Obtain release (L-30); request previous medical records										
	MD evaluation/review; document in progress notes										
	RN evaluation										
	IGRA or Mantoux skin test recorded in mm (if not previously done)										
	Chest X-ray (PA & Lateral if less than 18 years)										
Supervised sputum for AFB smear/culture according to protocol											
HIV testing, unless patient has knowledge of HIV+ status or has documented negative HIV test result within 14 days of TB diagnosis											
Labs per protocol or specific order											
Nutritional assessment											
Treatment	Drug regimen according to protocol or specific order										
	Initiate DOT on all cases/suspects: Recommended Daily X 8 weeks, then daily or 3X/week (Mon/Wed/Fri) until completion of adequate therapy; document DOT on TB-206; other DOT dosing schedules may be ordered.										
	Pyrazinamide X2 months and ethambutol X2 months (or until susceptibilities are reported and client's organism is known to be pan sensitive)										
	Vitamin B6 (if pregnant, diabetic, at risk for peripheral neuropathy)										
Obtain Informed Consent form TB-411 (TB-411A, if Spanish speaking, only) initially and for any drugs added to regimen.											
Consultation	Obtain expert consult for drug resistant cases, complicated adult/pediatric cases or client who remains symptomatic or sputum positive after 2 months' therapy; written consult in client record										
Toxicity/Clinical Assessment	Clinical assessment according to protocol; document (TB-205) and progress note as appropriate										
	Visual acuity (Sloan or Snellen) and color discrimination (Ishihara Plates) initially and monthly if on EMB or Rifabutin; document (TB-205)										
	Hearing sweep check initially and monthly if on amikacin, capreomycin, kanamycin or streptomycin; document (TB-205)										

TB 201- Case Management Plan for Outpatient Care - Revised 08/2017

Administering the medications



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Ensure that the patient answers each question about toxicity before medications are given.
- Ensure that the correct dosage is given at each patient encounter.
- Ask open-ended questions in addition to the closed ended questions.





Patient monitoring

- The frequency with which you monitor the patient depends on how the patient is responding to treatment.
 - How is the patient doing clinically?
 - Are there new s/sx of toxicity?
 - How were the baseline labs?
 - What do your standing delegation orders allow you to do?
- Patient should have a toxicity screening form completed at least monthly.





Drug side effects

- Unpleasant, but usually mild
- Generally resolve during or after treatment.
- Do not usually require changes in therapy.
- Can include:
 - Gas or bloating
 - Mild nausea
 - Discoloration of body fluids (RIF)
 - Photosensitivity (RIF)
 - Rash (minor)
 - Fatigue





Drug adverse effects

- Change in vision
- Hepatotoxicity
- Significant GI problems (severe vomiting)
- CNS toxicity
- Neurotoxicity
- Renal toxicity
- Bleeding problems
- Rash (severe, systemic involvement)



Adverse Drug Reactions



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- More serious than side effects.
- May be life threatening
- Require modification of dose/discontinuation medications.
- Must be reported to the treating physician immediately.





TEXAS
Health and Human Services

Texas Department of State
Health Services

1st line TB medications

- Isoniazid
 - Kills rapidly dividing TB cells.
- Rifampin
 - Kills rapidly dividing TB cells.
 - Has some effect on semi-dormant TB cells.
- Pyrazinamide
 - Kills semi-dormant TB cells.
- Ethambutol
 - Protects against developing rifampin resistance.


Common adverse effects in 1st line medications



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Isoniazid
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Fatigue, jaundice, abdominal pain, dark urine, light stools, nausea, poor appetite
 - Can cause peripheral neuropathy
 - Numbness/tingling to hands and feet.
 - Rash



Common adverse effects in 1st line medications



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Rifampin
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Can cause low platelet count.
 - Need baseline PLTs and monitoring for thrombocytopenia.
 - Orange discoloration of body fluids.
 - Can damage kidneys and cause decreased urine output.
 - Interacts with many other medications.
 - Get patient's medication list and review with your physician.



Common adverse effects of 1st line medications



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Pyrazinamide
 - Increases liver functions
 - Watch LFTs at baseline and throughout treatment.
 - Watch Uric Acid level and monitor for joint pain.
 - Fatigue, jaundice, abdominal pain, dark urine, light stools, nausea, poor appetite
 - Can cause GI problems (upset stomach, lack of appetite)
 - Can cause rash.



Common adverse effects in 1st line medications



TEXAS
Health and Human
Services

Texas Department of State
Health Services

- Ethambutol
 - Can cause eye damage
 - Blurred vision
 - Change in color vision
 - Monitor kidney functions to adjust dosage.
 - Can cause rash





TEXAS
Health and Human Services

Texas Department of State
Health Services

Fluroquinolones

Drug	Standard adult Dosing	Considerations	Side Effects
Moxifloxacin	40mg once daily, PO or IV	Good CNS Penetration	GI upset, dizziness, hypersensitivity, photosensitivity, headaches, arthralgias, tendonitis, tendon rupture (rare), CNS irritability, QTc prolongation, thrush, peripheral neuropathy, elevated liver enzymes (rare hepatotoxicity with moxifloxacin)
Levofloxacin	750-1,000 mg once daily, PO or IV	Good CNS penetration; adjust dose with creatine clearance < 30; avoid caffeine, milk-based products, antacids, or mineral supplements within 2 hrs. of medication	



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Vision Screening

**Ishihara Testing
Snellen Eye Exam**









TEXAS
Health and Human Services

Texas Department of State
Health Services

Ishihara Test

- Designed to give quick & accurate assessment of color vision
- Most effectively done in room with adequate daylight
- Held 75 cm from the patient (approx. arm length)
- Sit & tilt plate at right angle to patient's line of vision
- Screen all plates







Normal (S,M,L)



Protan or Red/Green (S,M)



Deutan or Red/Green (S,L)



Tritan or Blue/Yellow (M,L)



TEXAS

Health and Human Services

Texas Department of State
Health Services

Visual Acuity

- Place Snellen Chart on wall & have patient 20 feet from chart
- Have patient cover one eye at a time to read chart, recording the visual acuity for each eye, then with both eyes uncovered
- If patient misses only one letter have them continue reading the next line
- Record the last line the patient reads accurately
- If initial screen was conducted with corrective lenses(glasses/contacts), follow-up screens must be done the same.
- Change of 1 or more lines from initial screen in either one or both eyes must be reported to physician **immediately**



Managing & Monitoring Visual Toxicities

1. Baseline & monthly visual acuity test (Snellen chart)
2. Baseline & monthly color discrimination test (Ishihara tests)
3. If change from baseline:
 - a. Hold Rx
 - b. Refer for Ophthalmologic evaluation
 - c. Permanent vision impairment if ethambutol continued



TEXAS
Health and Human Services

Texas Department of State
Health Services

Toxicity

Stop Medication ASAP with suspicion of vision, hearing loss, hepatitis, severe rash

In most cases vision loss is irreversible

Stopping medication halts extensiveness of damage

Better to miss a few doses vs disability



TEXAS
Health and Human Services

Texas Department of State
Health Services



Rashes/Itching

- All TB drugs can cause a rash
- If the rash is not severe, the patient may be able to be treated with antihistamines or low dose prednisone.
- Assess the rash
 - Location
 - Does it itch?
 - When did it start?
 - What does it look like?
 - Has the patient tried any new products – food, perfume, laundry detergent.
 - Have you ruled out other involvement?



Conclusion

1. Initial and ongoing assessment for medication side effects or adverse effects is crucial in maintaining a safe course of treatment for the patient.
2. Work with the patient and your treating physician to determine cause of side effects and how to address them.
3. You are the eyes and ears of the physician and the mouthpiece of the patient.



TEXAS
Health and Human Services

Texas Department of State
Health Services



Helpful links

- Heartland National TB Center website
 - <http://www.heartlandntbc.org/products/> (to print out educational items)
- CDC TB website
 - <https://www.cdc.gov/tb/default.htm>
- Treatment guidelines
 - https://www.cdc.gov/tb/publications/guidelines/pdf/clin-infect-dis.-2016-nahid-cid_ciw376.pdf
- TB education resources
 - <https://findtbresources.cdc.gov/>



TEXAS
Health and Human
Services

**Texas Department of State
Health Services**

Thank you
